Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Participants who have completed the 6-week trial P05688 can be screened for eligibility for
this 26-week extension study in which they will continue treatment. The purpose of this trial
is to evaluate the long-term safety of 2.5 and 5 mg asenapine administered sublingually twice
daily (BID) in schizophrenia participants. Olanzapine administered 15 mg orally once daily
(QD) is used as an active control.